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Purpose: CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered an 
important marker that represents the subset population of cancer stem-like cells. The purpose of the 
present study is to isolate cancerous stem-like cells from normal healthy volunteers and prostate cancer 
patients (CD133
+
) which also express MDR1 and to ascertain the influence of Oct-4 on ‘stem-ness’ and 
differentiation of these CD133
+
 cells towards epithelium. 
Methods: CD133
+
 cells were isolated using magnetic beads from normal healthy volunteers and 




). The isolated cells were analyzed using flow 




 cells were cultured 
in presence and absence of antihuman Oct-4 blocking antibody. 
Results: PC-CD133
+
 cells displayed higher Oct-4 expression with the ability to self-renew and may 
represent a reservoir with differentiation potential for generating prostate cancer cells. Furthermore, PC-
CD133
+
 cells highly co-expressed the multiple drug-resistant marker MDR1. The treatment with Oct-4 
blocking antibody can specifically block the capability of PC-CD133
+
 cells to differentiate into prostate 
epithelial cells bearing CD57. 
Conclusion: PC-CD133
+
 cells displayed a higher Oct-4 expression with the ability to self-renew and 
may represent a reservoir with differentiation potentials for progression of prostate cancer. The MDR1 
expression of PC-CD133
+
 cells in vitro and in vivo is partially due to preferential activation of Oct-4 gene 
expression. 
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INTRODUCTION 
 
Prostate cancer is one of the leading causes 
of cancer-related deaths in males. 
Radiotherapy and chemotherapy play 
significant and crucial roles in clinical prostate 
cancer treatment to achieve prolonged patient 
survival. Autopsy studies show that many 
older men (and even younger men) who died 
of other diseases also had prostate cancer 
that never caused a problem during their lives. 
These studies showed that seven or eight out 
of ten men had prostate cancer by the age of 
80 years
1
. To improve the patient survival 
rate, investigation to elucidate the mechanism 
of tumorigenesis of prostate cancer is needed. 
Recent data have demonstrated that tumors 
contain a small subpopulation of cells, i.e., 
cancer stem-like cells (CSCs) or cancer-
initiating cells (CICs), which exhibit a self-
renewing capacity and are responsible for 
tumor maintenance and metastasis. Stem 
cells have been isolated by their ability to 
efflux Hoechst 33342 dye
2
 and are referred to 
as the ‘‘side population (SP)’’. Our previous 
publication
11
 showed MDR1 in stem cells, 
enhanced the migration and homing of 
cultured bone marrow stem cells.  
  
A transmembrane glycoprotein, CD133 
(prominin-1) was first recognized in CD34
+
 
progenitor populations from adult blood, bone 
marrow, and fetal liver cells. Recently, CD133 
has been considered an important marker to 
represent the subset population of CSCs in 
leukemia, brain tumors, retinoblastoma, renal 
tumors, pancreatic tumors, colon carcinoma, 
prostate carcinoma, and hepatocellular 
carcinoma. However, the gene regulation 
mechanisms in maintaining the self-renewal 
and drug resistant properties in putative 
cancer stem-like cells of prostate tumors are 
still unclear. 
 
Oct-4, a member of the family of POU-domain 
transcription factors, is expressed in 
pluripotent embryonic stem (ES) and germ 
cells. Oct-4 activates transcription via octamer 
motifs, and Oct-4 binding sites have been 
found in various genes, including fgf4 
(fibroblast growth factor 4) and pdgfαr 
(platelet-derived growth factor α receptor). 
This suggests that Oct-4 functions as a 
master switch during differentiation by 
regulating the pluripotent potentials of the 
stem cell, and Oct-4
3-5 
plays a pivotal role in 
mammalian development. 
 
In this study, CD133-positive cells (CD133
+
) 
were isolated from normal volunteers’ (NV) 
and prostate cancer patients’ tissue samples 
(PC) and investigated for their ability to 
differentiate into prostate cancer epithelial 
cells bearing CD57.  
 
MATERIALS AND METHODS 
 
All normal and prostate cancer tissues were 
kindly donated by Drs. Satish Kumar and S. 
N. Chary (Urologist) from those obtained from 
volunteers in NRI Hospital, Krishna (Dist), 
Andhra Pradesh, India. The study was 
approved by Institutional animal ethics 




 population from 
prostate cancer biopsies 
 
The study was approved by the Institutional 
Ethics Committee/Institutional Review Board 
of NRI hospital. Biopsy samples from both 
normal (n=6) and prostate cancer patients 
(n=10) were digested with Trypsin-
collagenase mixture (Sigma) to dissociate 
cells from tissues. From this fraction, cells 
were selected for CD133 expression (Miltenyi 
Biotech) using magnetic beads as described 
by the manufacturer and were analyzed for 
the presence of CD133 (AC133, Miltenyi 
Biotech) and MDR1 (Sigma-Aldrich). The 
purity of CD133
+
 cells in the sorted samples 
was routinely greater than 92% and nearly all 
these cells also expressed MDR1.   
 
Western blot analysis for Oct-4, CD133 and 
MDR1 
 
The isolated cells from normal and prostate 
cancer patients’ biopsies were lysed by 
adding SDS sample buffer containing 1 mM 
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orthovanadate, and the samples were 
processed for Western Blotting. The 
expression patterns of Oct-4, MDR1 (both 
from Sigma-Aldrich) and CD133 (Miltenyi 
Biotech) were detected in normal and prostate 




 population from 
peripheral blood samples 
 
Mononuclear cells were obtained from normal 
and prostate cancer patients’ buffy coats, on a 
Ficoll gradient (Biocoll 1077, Sigma). From 
this fraction, cells were selected for CD133 
expression (Miltenyi Biotech) using magnetic 
beads as described by the manufacturer and 
were analyzed for the presence of CD133 
(AC133, Miltenyi Biotech) and MDR1. The 
purity of CD133
+
 cells in the sorted samples 
was routinely greater than 94% and nearly all 
these cells also expressed MDR1. The above 
method is also used for isolation of CD133
+
 






The above isolated cells from peripheral blood 
as well as from prostate tissues, were cultured 
on plates coated with fibronectin (50 µg/ml) in 
Iscove’s modified Dulbecco medium (IMDM), 
BSA (2 mg/ml), bovine transferrin (200 µg/ml), 
human insulin (10 µg/ml), hydrocortisone (2 
µM), hepatocyte growth factor (HGF) (20 
ng/ml) and GM-CSF (20 ng/ml). Cells were 
cultured in serum-free basal medium 
(Himedia) for 8-10 days after which half of the 
medium was replaced with fresh medium on 
alternate days. The cultured cells were 
trypsinzed and analyzed for various markers 
like CD133 and MDR1. In some experiments 
we used blocking rabbit anti-human Oct-4 
antibody to block Oct-4 antigen in cell culture. 
The medium containing the antibody and 
growth factors was also replaced with fresh 




About 5 x 10
5
 freshly isolated cells from 
patient biopsies and peripheral blood samples 
were stained by incubating with 50 µl of 
diluted primary antibodies at 4
o
C for 45 min. 
The cells were washed and stained with 
secondary antibody and then again washed 
and fixed with 0.2% paraformaldehyde. The 
antibodies used in this study were biotinylated 
anti-CD133 (Miltenyi Biotech, Labmate (Asia) 
Pvt., Ltd, India), mouse anti-human MDR1 
(Clone F4, Sigma Aldrich), rabbit anti-human 
Oct-4 (Sigma Aldrich), anti-CD57 (BD 
Biosciences – Pharmingen. Clone NK-1, 
labeled with FITC), anti-biotin-PE (Miltenyi 
Biotech), streptavidin-FITC (Pharmingen), and 
isotype control antbodies were also procured 
from Pharmingen. The cells were analyzed on 
a customized BD FACS Caliber (BD 
Biosciences, San Jose, CA) using filters of 
530/28 BP for FITC and 575/26 BP for PE 





Isolation and characterization of prostate 
cancer-derived CD133-positive cells 
 
Using the magnetic bead method, we isolated 
CD133
+
 cells from tissue samples of six 
normal healthy volunteers and ten prostate 





cells, FACS was 
used for the detection of the expression profile 





) subset was 
isolated from the PC tissues (Fig 1). 
Peripheral blood derived CD133
+
 cells were 
isolated from normal healthy volunteers and 
prostate cancer patients. This isolation also 




(Fig 2). Surprisingly prostate cancer patients’ 
tissues and peripheral blood samples derived 
CD133
+
 cells showed 80-90% also positive for 
MDR1 (Figs 1 & 2). We also found that in 
CD133
+
 cell fraction, MDR1
+
 cells were 
significantly less in tissues of normal non-
diseased volunteers than prostate cancer 
patients (Figs 1 & 2). 
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Figure 1: Cellular characterization of CD133/ MDR1/ CD133 & MDR1 in prostate tissues of 
normal and cancer patients 
 
Note: Fig 1A represents isotype controls for CD133 and MDR1 in normal healthy volunteers’ prostate 








cells in normal healthy 
volunteers’ prostate tissue samples (n=6). Results are expressed in mean ± SEM. Fig 1B represents 









cells in prostate cancer patients’ tissue samples(n=10). Results are 


































































































Isotype controls for CD133 & MDR1
 
Figure 2: Cellular characterization of CD133/ MDR1/ CD133 & MDR1 in peripheral blood 
samples of normal and cancer patients 
 
Note: Fig 2A represents isotype controls for CD133 and MDR1 in normal healthy volunteers’ peripheral blood samples 








cells in normal healthy volunteers’ peripheral blood 
samples (n=6). Results are expressed in mean ± SEM. Fig 2B represents isotype controls for CD133 and MDR1 in 









in prostate cancer patients’ peripheral blood samples (n=10). Results are expressed in mean ± SEM. 
 
Blotting analysis for Oct-4, MDR1 and 
CD133 
 
Western blot results suggested that the 
expression level of Oct-4, self-renewal and 
stem-ness protein in PC-CD133
+
 cells was 
significantly up-regulated than that in normal 
healthy volunteers (Fig 3A). To validate this 
finding, we examined the expression of Oct-4 
in peripheral blood also. The amounts of Oct-4 
protein in isolated PC-CD133
+
 cells were 
significantly more than in normal healthy 
volunteers (Fig 3B).  
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Figure 3: Western blot analysis of Oct-4, MDR1 and CD133 of prostate tissues in both normal 
healthy volunteer and prostate cancer patients. 
 
Note: Fig 3A represents the samples are from prostate tissues of prostate cancer patients and normal healthy 
volunteers. Fig 3B represents the samples from peripheral blood leucocytes of prostate cancer patients and normal 
healthy volunteers. 
 
Role of Oct-4 Expression in CD133
+
 
differentiation towards prostate epithelium 
 
To investigate whether Oct-4 expression plays 
a role in maintaining self-renewal or cancer 
stem-like properties in PC-CD133
+
cells, we 
used the rabbit anti-human Oct-4 blocking 
antibody (3µg/ml), from day 1 to 8-10 days of 
culture of tissue and peripheral blood derived 
CD133
+ 
cells of both normal healthy 
volunteers and prostate cancer patients. We 
found that treatment of blocking antihuman 
Oct-4 antibody in CD133
+
 cell differentiation 
could significantly interfere with the 
capabilities of differentiation towards prostate 
epithelium bearing CD57. However, this was 
not the case with NV-CD133+ differentiation 
(Figs 4A and 4B). 
 
Statistical analysis  
 
Data were analyzed by one–way ANOVA 
followed by Dunnett’s t-test using 
computerized Graph Pad Instat
®
 version 3.05 
(Graph Pad software, U.S.A.). 
DISCUSSION 
 
Oct-4 has been suggested as one of four 
major factors that render the reprogramming 
capability
3-5
 of adult cells into germline-
competent-induced pluripotent stem cells. 
Recently, Oct-4 transcript can be consistently 
detected in human embryonal carcinomas, 
testicular germ cell tumors
6-9
, seminomas, and 
bladder carcinomas. The expression of Oct-4 
has further been shown in human breast 
cancer stem-like cells
10
, suggesting that its 
expression may be implicated in self-renewal 
and tumorigenesis via activating its 
downstream target genes. Here we report the 
isolation of CD133-positive cells (PC-CD133
+
) 
from clinical tissue samples and peripheral 
blood samples. PC-CD133
+
 cells showed 
strong stem-ness and differentiation in vitro 
and in vivo (Figs 1, 2, and 4). PC-CD133
+
 
cells also displayed significant expression 
profiles of Oct-4 and MDR1 (Fig 3). We also 
demonstrated that Oct-4 regulated 
differentiation into prostate epithelium 
expressing CD57 in PC-CD133
+
 (Fig 4).  
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Figure 4: Cellular characterization of cultured CD133
+
 cells 




 of normal healthy volunteers’ (n=6) and prostate cancer 




cells cultured for 8-10 fays. Results are expressed in mean ± SEM. (n=6) 










cells cultured for 8-10 fays. Results are expressed in mean ± SEM. (n=6) significance levels ** P<0.01, 
as compared with the respective control. In all the experiments (3µg/ml) of anti-human Oct-4 blocking antibody was used 
through out culturing for 8 to 10 days. 
 
Indeed, Oct-4 functions as a master switch 
during differentiation
31–33
 by regulating the 
pluripotent potential in stem cells.  
 
Using the blocking antihuman Oct-4 blocking 
antibody in PC-CD133
+
 cells in culture, our 
data showed that the treatment of Oct-4 
blocking antibody can block the differentiation 
of PC-CD133
+
 cells towards epithelial cells 
bearing CD57 (Fig 4). To our knowledge, this 
is the first study to show that Oct-4 expression 
plays a crucial role in maintaining self-renewal 
and cancer stem-like properties in PC-CD133
+
 
cells. The property of resistance to 
chemotherapy (MDR1) and irradiation 
treatment is the major clinical criterion to 
characterize ‘‘cancer stem-like cells (CSCs)’’.  
 
The existence of cancer stem-like cells may 
explain why conventional anti-cancer 
therapies
1,12,13
 are able only to suppress or 
shrink a tumor but often cannot completely 
eradicate it, resulting in eventual recurrence. 
These results indicate that the up-regulated 
expression of Oct-4 in PC-CD133
+
 cells may 
contribute to the development of chemo-radio 
resistance in patients with prostate cancer. 
Recent studies have revealed that the human 
ABCG2 transporter is a P-glycoprotein that 
causes multidrug resistance (MDR1)
13,14
 
including mitoxantrone, doxorubicin, and 
topoisomerase I inhibitors of irinotecan, 
topotecan, and 7-ethyl-10-hydroxycamp-
tothecin (topoisomerase inhibitor) and gefitinib 
(an inhibitor of EGF receptor) in patients with 
lung cancer. Monzani and colleagues
15
 further 
showed that cancer stem-like cells derived 
from the melanoma cell line highly 
coexpressed CD133 and MDR1 markers with 
enhanced tumorigenic potential. In this study, 
we found that PC-CD133
+
 cells highly co-
expressed with MDR1 showing resistance to 
conventional treatment methods compared 
with NV-CD133
+
 (Figs 1 and 2). Interestingly, 
a significant down-regulating of MDR1 
expression and differentiation marker CD57 
expression of PC-CD133
+
 were observed 
when the antihuman Oct-4 blocking antibody 
treatment was given (Fig 4). Thus, more 
studies are needed to investigate whether 
over-expression of Oct-4, CD133, and/or 





We demonstrated that PC-CD133
+
 cells 
display a higher Oct-4 expression with the 
ability to self-renew and may represent a 
reservoir with differentiation potentials for 
progression of prostate cancer. The MDR1 
expression of PC-CD133
+
 cells in vitro and in 
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vivo is partially due to preferential activation of 
Oct-4 gene expression. In addition, these data 
support that the up-regulated expression of 
Oct-4 play an important role in the 
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